53. Sjogren syndrome
234 clinical trials,   270 drugs   (DrugBank: 85 drugs),   49 drug target genes,   174 drug target pathways

Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01759108
(ClinicalTrials.gov)
March 13, 202023/12/2012Rebamipide AND Sjögren SyndromeRebamipide for the Treatment of Xerostomia in Sjögren SyndromeImproving Symptoms of Dry Mouth in Sjogren's SyndromeDrug: RebamipideUniversity of AlexandriaNULLRecruitingN/AN/AAll55N/AEgypt
2NCT03608761
(ClinicalTrials.gov)
February 6, 20179/7/2018Comparison Between Rebamipide 2% Versus Autologous SerumComparison Between Rebamipide 2% Versus Autologous Serum in the Treatement of the Moderate to Severe Dry Eye Associate With Sjögren Syndrome. Pilot, Crossed, Controled, Randomized And Open StudyDry Eye Syndromes;Sjögren SyndromeDrug: Rebamipide;Biological: autologous serum;Other: autologous serum and rebamipide 2%Hospital Nacional Profesor Alejandro PosadasNULLCompleted18 YearsN/AFemale21Phase 4Argentina
3JPRN-UMIN000013234
2014/04/0101/04/2014Effect of the dual treatment of diquafosol sodium and rebamipide on dry eye syndrome related to chronic graft versus host disease and Sjogrens syndrome Dry eye related to chronic GVHD and Sjogren s syndromeDiquafosol sodium and rebamipide ophthalmic solution
Artifical tears, vitamin A ophthalmic solution, or/and sodium hyaluronate ophthalmic solution
Keio University School of MedicineNULLComplete: follow-up complete20years-old75years-oldMale and Female20Not applicableJapan
4JPRN-UMIN000010710
2013/05/1515/05/2013Effective treatment of rebamipide on xerostomia in Sjogrens syndrome patients:a pilot study -a double-blind placebo-controlled trial- Xerostomia in Sjogrens syndromeRebamipide was administered orally at 100 mg each time three times a day after meals for 8 weeks.
Placebo was administered orally three times a day after meals for 8 weeks.
Tochigi medical centerNULLComplete: follow-up complete20years-old80years-oldMale and Female60Phase 2Japan
5JPRN-UMIN000008427
2012/07/1313/07/2012Evaluation of efficacy of rebamipide ophthalmic suspension in patients with dry eye associated with Sjogren's syndrome. Patients with dry eye associated with Sjogren's syndrome.Mucosta ophthalmic suspension UD2%Kanazawa Medical UniversityNULLComplete: follow-up complete20years-oldNot applicableMale and Female30Not selectedJapan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00233363
(ClinicalTrials.gov)
March 20054/10/2005Exploratory Study for Dry Mouth in Patients With Sjögren’s SyndromeAn Exploratory Study of Rebamipide to Evaluate Efficacy and Safety in the Treatment of Dry Mouth in Patients With Sjögren’s SyndromeXerostomia;Sjogren's SyndromeDrug: RebamipideOtsuka Pharmaceutical Co., Ltd.NULLCompleted20 YearsN/ABoth100Phase 2Japan
7JPRN-JapicCTI-050036
06/09/2005Exploratory study of rebamipide to evaluate the efficacy and safety in treatment of dry mouth in patients with Sjogren's syndromeExploratory study of rebamipide to evaluate the efficacy and safety in treatment of dry mouth in patients with Sjogren's syndrome Dry mouth in patients with Sjogren's syndromeIntervention name : Rebamipide
Dosage And administration of the intervention : Oral
Otsuka Pharmaceutical Co., Ltd.NULL20BOTHPhase 2NULL